1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,500 | 11,900 | 09:12 | |
| 11,500 | 11,900 | 09:12 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA | 2 | GlobeNewswire (USA) | ||
| 18.09. | MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development | 1 | GlobeNewswire (USA) | ||
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.08. | MiNK Therapeutics stock rating upgraded to Buy by H.C. Wainwright on financial results | 3 | Investing.com | ||
| 14.08. | MiNK Therapeutics GAAP EPS of -$1.06 misses by $0.51 | 4 | Seeking Alpha | ||
| 14.08. | MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results | 130 | GlobeNewswire (Europe) | Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant... ► Artikel lesen | |
| 14.08. | MiNK Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | MiNK Therapeutics: H.C. Wainwright stuft Aktie nach Kursrallye auf "Neutral" herab | 17 | Investing.com Deutsch | ||
| 15.07. | MiNK Therapeutics stock rating downgraded to Neutral by H.C. Wainwright | 2 | Investing.com | ||
| 15.07. | Mink Therapeutics stock tumbles on $50 million stock offering | 5 | Investing.com | ||
| 15.07. | MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy | 1 | GlobeNewswire (USA) | ||
| 15.07. | Nach Kursrallye von über 460 %: MiNK Therapeutics kündigt Kapitalerhöhung über 50 Mio. US-Dollar an | 5 | Investing.com Deutsch | ||
| 14.07. | William Blair stuft MiNK-Therapeutics-Aktie nach 700-%-Rallye herab | 9 | Investing.com Deutsch | ||
| 14.07. | William Blair downgrades MiNK Therapeutics stock to Market Perform after 700% surge | 3 | Investing.com | ||
| 14.07. | MiNK Therapeutics stock maintains Buy rating at H.C. Wainwright after case study publication | 1 | Investing.com | ||
| 14.07. | MiNK Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 14.07. | MiNK Therapeutics stock falls after William Blair downgrade | 4 | Investing.com | ||
| 14.07. | XFRA 6Q40: WIEDERAUFNAHME/RESUMPTION | 313 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 11.07. | Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? | 11 | Benzinga.com | ||
| 11.07. | MiNK Therapeutics Stock Skyrockets 643% On Cancer Remission Case | 5 | RTTNews | ||
| 11.07. | Durchbruch in der Krebstherapie: Aktie von MiNK Therapeutics schießt um 200 % in die Höhe | 48 | Investing.com Deutsch |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 38,400 | 0,00 % | EQS-News: BB BIOTECH AG: BB Biotech wird in den SPI ESG Index aufgenommen | EQS-News: BB BIOTECH AG
/ Schlagwort(e): ESG
BB Biotech wird in den SPI ESG Index aufgenommen
22.09.2025 / 07:00 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
| VIKING THERAPEUTICS | 21,765 | +1,12 % | Viking Therapeutics: Wo bleibt der nächste Katalysator? | Der Wettbewerb im Markt für Adipositas- und Diabetesmedikamente nimmt weiter Fahrt auf. Während Konkurrenten durch milliardenschwere Übernahmen Schlagzeilen machen, kämpft Viking Therapeutics mit gemischten... ► Artikel lesen | |
| NOVOCURE | 11,105 | +1,23 % | Novocure Announces Approval For Optune Lua In Japan | WASHINGTON (dpa-AFX) - Novocure (NVCR) announced that Japan's Ministry of Health, Labour and Welfare approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,700 | +0,24 % | Oxford Nanopore Technologies: ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology | New adventitious viral agent (AVA) detection test offers rapid, sensitive, and affordable viral screening for biomanufacturers
ViruSure, a global leader in pathogen safety testing for biopharmaceuticals... ► Artikel lesen | |
| MEREO BIOPHARMA | 1,570 | +2,95 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights | Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027... ► Artikel lesen | |
| BIOLINERX | 2,995 | +0,84 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ASSERTIO | 0,925 | -3,64 % | Assertio Holdings, Inc.: Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN (clobazam) Oral Film, CIV | New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsyStudy addresses lack of awareness... ► Artikel lesen | |
| ROIVANT SCIENCES | 12,780 | -0,43 % | Roivant Sciences auf der Bank of America Konferenz: Strategischer Fokus auf Pipeline und Rechtsstreitigkeiten | ||
| APPLIED THERAPEUTICS | 0,465 | -3,83 % | Applied Therapeutics Reports Second Quarter 2025 Financial Results | - CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE... ► Artikel lesen | |
| AKERO THERAPEUTICS | 40,030 | +0,96 % | Akero Therapeutics Inc.: Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH | SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic... ► Artikel lesen | |
| ARVINAS | 7,750 | 0,00 % | Arvinas stock downgraded by BofA as Pfizer partnership shifts | ||
| REVOLUTION MEDICINES | 36,000 | -1,10 % | Revolution Medicines, Inc.: Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma | Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability Highly encouraging initial clinical... ► Artikel lesen | |
| JANUX THERAPEUTICS | 21,750 | -4,65 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| WEREWOLF THERAPEUTICS | 2,000 | 0,00 % | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | - WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year - - First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 9,990 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen |
Das Unternehmen MINK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +4,20 % bei einem Aktienkurs von 12,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.